{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:31:40Z","timestamp":1791189100710,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ejphar.2008.09.008","type":"journal-article","created":{"date-parts":[[2008,9,21]],"date-time":"2008-09-21T13:02:59Z","timestamp":1222002179000},"page":"27-33","source":"Crossref","is-referenced-by-count":57,"title":["Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors"],"prefix":"10.1016","volume":"597","author":[{"given":"Yoshihiro","family":"Tadori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.09.008_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10401230490521954","article-title":"Aripiprazole augmentation in treatment-resistant depression","volume":"16","author":"Barbee","year":"2004","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.jcp.0000169419.38899.5b","article-title":"Aripiprazole in schizophrenia with cocaine dependence: a pilot study","volume":"25","author":"Beresford","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2008.09.008_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v66n0613","article-title":"Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole","volume":"66","author":"Brown","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neuropharm.2007.05.006","article-title":"Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1\/2 activation","volume":"53","author":"Bruins Slot","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2008.09.008_bib7","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which cause 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.09.008_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2007.07.002","article-title":"No association between the DRD3 Ser9Gly polymorphism and schizophrenia","volume":"98","author":"Fathalli","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2008.09.008_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","article-title":"Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression","volume":"161","author":"Goldberg","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","article-title":"Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons","volume":"20","author":"Gurevich","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.09.008_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0006-2952(99)00101-X","article-title":"Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3\u20325\u2032-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese hamster ovary (CHO) cells","volume":"58","author":"Hall","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.09.008_bib12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/jmg.2004.020941","article-title":"The ser9gly SNP in the dopamine D3 receptor causes a shift from cAMP related to PGE2 related signal transduction mechanisms in transfected CHO cells","volume":"41","author":"Hellstrand","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ejphar.2008.09.008_bib13","doi-asserted-by":"crossref","first-page":"10753","DOI":"10.1073\/pnas.0508189103","article-title":"A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor","volume":"103","author":"Jeanneteau","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2008.09.008_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib16","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1093\/nar\/15.20.8125","article-title":"An analysis of 5\u2032-noncoding sequences from 699 vertebrate messenger RNAs","volume":"15","author":"Kozak","year":"1987","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2008.09.008_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF03033360","article-title":"The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia","volume":"10","author":"Krystal","year":"2006","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ejphar.2008.09.008_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.neuropharm.2005.04.022","article-title":"The dopamine D3 receptor and drug dependence: effects on reward or beyond?","volume":"49","author":"Le Foll","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2008.09.008_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0031-6997(24)01327-9","article-title":"The D3 dopamine receptor: neurobiology and potential clinical relevance","volume":"49","author":"Levant","year":"1997","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2008.09.008_bib20","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1006\/bbrc.1996.1296","article-title":"Proposed schizophrenia-related gene polymorphism: expression of the ser9gly mutant human dopamine D3 receptor with the Semliki Forest virus system","volume":"225","author":"Lundstrom","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2008.09.008_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2008.09.008_bib22","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib23","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1471-4159.2007.04660.x","article-title":"Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation","volume":"102","author":"Novi","year":"2007","journal-title":"J. Neurochem."},{"issue":"Suppl 4","key":"10.1016\/j.ejphar.2008.09.008_bib24","doi-asserted-by":"crossref","first-page":"S568","DOI":"10.1016\/S0924-977X(07)70884-2","article-title":"Efficacy of aripiprazole in the treatment of adolescents with schizophrenia","volume":"17","author":"Nyilas","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2008.09.008_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist","volume":"400","author":"Pilla","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2008.09.008_bib26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2008.09.008_bib27","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.264.19.2511","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2008.09.008_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187152706784111551","article-title":"The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders","volume":"5","author":"Sokoloff","year":"2006","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ejphar.2008.09.008_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","article-title":"Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic","volume":"515","author":"Tadori","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.09.008_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2007.07.031","article-title":"Difference in agonist\/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912","volume":"574","author":"Tadori","year":"2007","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908009503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908009503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T01:14:10Z","timestamp":1738372450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908009503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":30,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0014299908009503"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.09.008","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}